Home
About
About CPD Network
Mission & Vision
Purpose
Governance
Compliance
Physician Organization Checklist
Microsites
Members
Experts
CMEX Databse
Contact
Login
Home
About
About CPD Network
Mission & Vision
Purpose
Governance
Compliance
Physician Organization Checklist
Microsites
Members
Experts
CMEX Databse
Contact
Login
FR
EN
Login
Program Resources
Program Slides
Program Handout
Program Bibliography
Review Papers
Initial injectable therapy in type 2 diabetes: key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin
Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility
Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes
Study Publications
BEYOND: Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
CREDENCE: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
DAPA-CKD: Dapagliflozin in Patients with Chronic Kidney Disease
DAPA-HF: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
ELEMENT-2: Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial.
Study Publications
EMPA-KIDNEY (Rationale): The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
EMPEROR-Preserved: Empagliflozin in Heart Failure with a Preserved Ejection Fraction
EMPEROR-Reduced: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
SoliMix: Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial
SORELLA 2: Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine
Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
Guidelines
Diabetes Canada Pharmacologic Management: 2020 Update
Diabetes Canada Pharmacologic Management: 2020 Update – User’s Guide
2020 Clinical Practice Guidelines - Quick Reference Guide
2018 Diabetes Canada Guidelines, Chapter 14: Hypoglycemia
2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment
CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction
Other Resources and Tools
Antihyperglycemic Agents and Renal Function
Sick-Day Medication List
Health Canada. Biosimilar biologic drugs in Canada: Fact Sheet
Diabetes Canada Position Statement. Diabetes, Biologic Drugs, and Biosimilar Insulins
cpdisup
